WO2007113243A3 - Use of pde 5 inhibitors for the treatment of overactive bladder - Google Patents

Use of pde 5 inhibitors for the treatment of overactive bladder Download PDF

Info

Publication number
WO2007113243A3
WO2007113243A3 PCT/EP2007/053090 EP2007053090W WO2007113243A3 WO 2007113243 A3 WO2007113243 A3 WO 2007113243A3 EP 2007053090 W EP2007053090 W EP 2007053090W WO 2007113243 A3 WO2007113243 A3 WO 2007113243A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde
inhibitors
treatment
overactive bladder
inhibitor
Prior art date
Application number
PCT/EP2007/053090
Other languages
French (fr)
Other versions
WO2007113243A2 (en
Inventor
De Tejada Gorman Inigo Saenz
Frutos Javier Angulo
Original Assignee
Invest Y Clinica Andrologicas
De Tejada Gorman Inigo Saenz
Frutos Javier Angulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invest Y Clinica Andrologicas, De Tejada Gorman Inigo Saenz, Frutos Javier Angulo filed Critical Invest Y Clinica Andrologicas
Publication of WO2007113243A2 publication Critical patent/WO2007113243A2/en
Publication of WO2007113243A3 publication Critical patent/WO2007113243A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

The present invention relates to the use of an inhibitor of cyclic guanosine 3', 5'-monophosphate-specific phosphodiesterase type 5 (PDE 5) activity or of an inhibitor of PDE 5 expression for the manufacture of a medicament for the treatment and/or prophylaxis of overactive bladder disease. In addition, it further refers to pharmaceutical compositions containing said inhibitors of PDE 5 activity and expression.
PCT/EP2007/053090 2006-03-31 2007-03-30 Use of pde 5 inhibitors for the treatment of overactive bladder WO2007113243A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78791806P 2006-03-31 2006-03-31
US60/787,918 2006-03-31

Publications (2)

Publication Number Publication Date
WO2007113243A2 WO2007113243A2 (en) 2007-10-11
WO2007113243A3 true WO2007113243A3 (en) 2008-01-03

Family

ID=38092990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/053090 WO2007113243A2 (en) 2006-03-31 2007-03-30 Use of pde 5 inhibitors for the treatment of overactive bladder

Country Status (1)

Country Link
WO (1) WO2007113243A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1966506A (en) * 2005-11-17 2007-05-23 上海特化医药科技有限公司 Pyrromonazole pyrimidinone derivatives, method of producing them and use thereof
WO2008100886A1 (en) * 2007-02-12 2008-08-21 Auspex Pharmaceuticals, Inc. Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
CA2701844A1 (en) * 2007-10-02 2009-04-09 Dong-A Pharm. Co., Ltd. Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
WO2009056232A2 (en) * 2007-10-30 2009-05-07 Bayer Schering Pharma Aktiengesellschaft Combination of pde5 inhibitors with muscarinic receptor antagonists
EP2106792A1 (en) * 2008-04-02 2009-10-07 Pelvipharm Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MX2015001188A (en) * 2012-07-27 2015-05-07 Wellesley Pharmaceuticals Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143757A (en) * 1995-07-14 2000-11-07 Icos Corporation Chemical compounds
EP1317924A1 (en) * 2001-12-06 2003-06-11 Pfizer Limited Kit for reducing aching caused by pde-v inhibitors
WO2005049616A1 (en) * 2003-11-24 2005-06-02 Pfizer Limited 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY
WO2007039075A2 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143757A (en) * 1995-07-14 2000-11-07 Icos Corporation Chemical compounds
EP1317924A1 (en) * 2001-12-06 2003-06-11 Pfizer Limited Kit for reducing aching caused by pde-v inhibitors
WO2005049616A1 (en) * 2003-11-24 2005-06-02 Pfizer Limited 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY
WO2007039075A2 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAUGAN ALAIN ET AL: "The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b ]indole-1,3(2H)-dione analogues", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 46, no. 21, 9 October 2003 (2003-10-09), pages 4525 - 4532, XP002335512, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2007113243A2 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2006066937A3 (en) Mnk1 or mnk2 inhibitors
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
WO2008002245A8 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
IL195030A (en) Dpp iv inhibitor formulations
EA200802118A1 (en) HAVING INHIBITING ACTIVITY WITH RESPECT TO MNK1 / MNK2 THYENOPYRIMIDINES INTENDED FOR USE IN PHARMACEUTICAL COMPOSITIONS
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
WO2007017145A3 (en) Gsk-3 inhibitors
MX2009002239A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase.
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
BRPI0514736A (en) sigma receptor inhibitors
WO2004074266A8 (en) Hiv inhibiting 1,2,4-triazines
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
MX2007004248A (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors.
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
DK1885333T3 (en) Pharmaceutical formulation of apomorphine for buccal administration
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07727562

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07727562

Country of ref document: EP

Kind code of ref document: A2